期刊
THERAPEUTIC INNOVATION & REGULATORY SCIENCE
卷 52, 期 5, 页码 546-559出版社
SPRINGER HEIDELBERG
DOI: 10.1177/2168479018778282
关键词
TransCelerate; historical controls; propensity score; Bayesian; informative prior
资金
- UK Medical Research Council [MR/M013510/1]
- TransCelerate BioPharma Inc.
- MRC [MR/M013510/1] Funding Source: UKRI
The goal of clinical trial research is to deliver safe and efficacious new treatments to patients in need in a timely and cost-effective manner. There is precedent in using historical control data to reduce the number of concurrent control subjects required in developing medicines for rare diseases and other areas of unmet need. The purpose of this paper is to provide a review for a regulatory and industry audience of the current state of relevant statistical methods, and of the uptake of these approaches and the opportunities for broader use of historical data in confirmatory clinical trials. General principles to consider when incorporating historical control data in a new trial are presented. Bayesian and frequentist approaches are outlined including how the operating characteristics for such a trial can be obtained. Finally, examples of approved new treatments that incorporated historical controls in their confirmatory trials are presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据